The Effect of Pharmacist Intervention on the Use of Zostavax in a Community Pharmacy Setting

Summary

The purpose of this study is to determine whether pharmacist-driven patient interventions can have an effect on the number of herpes zoster (Zostavax) vaccinations given in a community pharmacy setting.

Conditions

• Herpes Zoster

Interventions

OTHER

Personalized letter

On Day 1 of the 2nd month, a personalized letter (addressing specific patient) was mailed to current pharmacy patients with indications for the Zostavax vaccine. Current patients were defined as those receiving at least one prescription medication from the pharmacy within 6 months. The personalized letter provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.

OTHER

Flyer advertisement

Beginning on Day 1 of the 2nd month, flyer advertisements were distributed with all pharmacy sales. Flyer advertisements provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.

OTHER

Newspaper press release

During the first week of the 2nd month, local newspapers published press releases. The press release provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.

Sponsors & Collaborators

• Merck Sharp & Dohme LLC

  collaborator INDUSTRY

• American Pharmacists Association

  collaborator OTHER

• University of Tennessee

  lead OTHER

Principal Investigators

• Lindsay J Ford, Pharm.D. · University of Tennessee Community Pharmacy Residency Program

• Sarah K Frank, Pharm.D. · University of Tennessee Community Pharmacy Residency Program

• Nina H Jaber, Pharm.D. · University of Tennessee Community Pharmacy Residency Program

• Stephan L Foster, Pharm.D. · University of Tennessee Community Pharmacy Residency Program

• Richard Randolph, Pharm.D. · University of Tennessee Community Pharmacy Residency Program

• Steve Lane, Pharm.D. · University of Tennessee Community Pharmacy Residency Program

• Cindy T Smith, Pharm.D. · University of Tennessee Community Pharmacy Residency Program

Study Design

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Model

FACTORIAL

Eligibility

Min Age

60 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2008-02-29

Primary Completion

2008-03-31

Completion

2008-03-31

Countries

• United States

Study Locations